Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T93440
|
||||
| Former ID |
TTDS00521
|
||||
| Target Name |
Interleukin-6 receptor
|
||||
| Synonyms |
CD126; IL-6R; IL6R; Membrane glycoprotein 80; gp80
|
||||
| Target Type |
Successful
|
||||
| Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
| Ankylosing spondylitis [ICD9: 720; ICD10: M08.1, M45] | |||||
| Cutaneous lupus erythematosus [ICD9: 710; ICD10: M32] | |||||
| Enthesopathy; Type 2 diabetes [ICD9:726, 250; ICD10: M76-M77.9, E11] | |||||
| Juvenile idiopathic arthritis [ICD9: 714.3; ICD10: M08.0] | |||||
| Melanoma [ICD9: 172; ICD10: C43] | |||||
| Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
| Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
| Severely active rheumatoid arthritis [ICD10: M05-M06] | |||||
| Function |
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
|
||||
| BioChemical Class |
Type I cytokine receptor
|
||||
| Target Validation |
T93440
|
||||
| UniProt ID | |||||
| Drugs and Mode of Action | |||||
| Drug(s) | Sarilumab | Drug Info | Approved | Severely active rheumatoid arthritis | [1] |
| Tocilizumab | Drug Info | Approved | Rheumatoid arthritis | [2], [3] | |
| CHU | Drug Info | Registered | Enthesopathy; Type 2 diabetes | [4] | |
| CNTO-136 | Drug Info | Phase 3 | Cutaneous lupus erythematosus | [5] | |
| Fezakinumabx | Drug Info | Phase 3 | Rheumatoid arthritis | [6] | |
| SA-237 | Drug Info | Phase 3 | Rheumatoid arthritis | [7] | |
| SAR153191 | Drug Info | Phase 3 | Ankylosing spondylitis | [8], [9] | |
| Tocilizumab | Drug Info | Phase 3 | Juvenile idiopathic arthritis | [2], [3] | |
| ALX-0061 | Drug Info | Phase 2 | Autoimmune diabetes | [10], [11] | |
| SBP-002 | Drug Info | Terminated | Melanoma | [12] | |
| Inhibitor | Alpha-D-Mannose | Drug Info | [13] | ||
| Modulator | CHU | Drug Info | [14] | ||
| FM-101 | Drug Info | [14] | |||
| Sarilumab | Drug Info | [15] | |||
| SBP-002 | Drug Info | [15] | |||
| Tocilizumab | Drug Info | [16] | |||
| Antagonist | SA-237 | Drug Info | [17] | ||
| Sant7 | Drug Info | [18] | |||
| SAR153191 | Drug Info | [19] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA (Edaravone) | ||||
| REF 2 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881). | ||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027532) | ||||
| REF 5 | ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health. | ||||
| REF 6 | ClinicalTrials.gov (NCT02531633) Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis. | ||||
| REF 7 | ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health. | ||||
| REF 8 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7999). | ||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027858) | ||||
| REF 10 | ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
| REF 11 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363). | ||||
| REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022850) | ||||
| REF 13 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 14 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). | ||||
| REF 15 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 16 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | ||||
| REF 17 | IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. | ||||
| REF 18 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
| REF 19 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.